Aspira Women's Health Inc. (AWH)

Market Cap	11.88M
Revenue (ttm)	8.96M
Net Income (ttm)	-14.80M
Shares Out	16.67M
EPS (ttm)	-1.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	48,406
Open	0.743
Previous Close	0.749
Day's Range	0.690 - 0.752
52-Week Range	0.670 - 5.650
Beta	1.39
Analysts	Buy
Price Target	4.40 (+517.54%)
Earnings Date	Nov 14, 2024

About AWH

Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company’s products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1’s high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeter...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1993
• Employees: 64
• Stock Exchange: NASDAQ
• Ticker Symbol: AWH
• Website: https://aspirawh.com

Financial Performance

In 2023, Aspira Women's Health's revenue was $9.15 million, an increase of 11.85% compared to the previous year's $8.18 million. Losses were -$16.69 million, -44.15% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for AWH stock is "Buy." The 12-month stock price forecast is $4.4, which is an increase of 517.54% from the latest price.

Price Target

$4.4

(517.54% upside)

Analyst Consensus: Buy